Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO Human Challenge Models (“HCMs”) selects ERT as a partner to improve the cardiac safety of its study volunteers, further reinforcing the scientific integrity of the Company’s pioneering biomedical research and development platform.
Retroscreen has today announced a strategic partnership with ERT to administer ERT’s proven centralised Electrocardiogram (ECG) solution and services to ensure the cardiac safety of volunteers participating in its ground-breaking human challenge studies. The centralised ECG solution includes ERT’s proprietary EXPERT® operating platform, which delivers complete and efficient cardiac safety study management and reporting, thereby assisting Retroscreen’s mission to accelerate and reduce the cost of bringing new therapeutics and diagnostics to market.
Amy Furlong, Executive Vice President and Product Line Executive, Cardiac and Enterprise Solutions, ERT commented “ERT shares a common objective with Retroscreen in our commitment to offer innovative solutions that deliver the highest standards of care for study participants. We look forward to a long and successful partnership as we integrate our EXPERT and hVIVO platforms to support the ground-breaking research and development of new therapies and diagnostics.”
Dr. Martin Johnson, Senior Medical Director at Retroscreen commented “Volunteer care and medical integrity are cornerstones of the pioneering work we do in the field of human challenge studies. Retroscreen is delighted to partner with ERT and looks forward to realising significant benefits from its centralised ECG solution, including even higher levels of volunteer and patient care, and continuing regulatory conformance.”
Notes to Editors:
Retroscreen Virology Group plc (www.retroscreen.com) is a rapidly growing life sciences company based in the UK pioneering a technology platform called hVIVO which uses human models of disease to study new drugs and investigate disease in healthy volunteers and certain patient populations in a safe, controlled environment.
Retroscreen has established itself as the world leader in this field through the provision of clinical services to third party study sponsors. To date, the Company has conducted over 35 clinical studies, involving more than 1800 volunteers for a range of leading industry, governmental and academic clients.
However, Retroscreen’s hVIVO platform has a much wider application in helping to understand illness better because the Company believes that the best way to understand human disease is by studying it in humans, not laboratory models.
ERT (www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COAs) – which includes patient, clinician, and observer reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labelling, and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.